Hookle, a Finland-based tech company, is advancing sustainable growth for over 30 million U.S. micro-businesses with its AI-powered social media marketing app. By simplifying digital marketing, Hookle ...

Industry leaders in health and science converged in downtown Raleigh Thursday to highlight the area’s latest advancements in ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election ...

Biogen Inc. (NASDAQ:BIIB) also benefits from its strong pipeline, which shows promise in areas like lupus and Alzheimer’s ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...

Needham forecasts Biogen revenues to remain stable until 2025, rising ~3% by 2026. Biogen will face ongoing challenges as expectations for Leqembi need to adjusted to more realistic levels.